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Although the biology of normal fracture healing is well understood (Bruder et al., 1994; Yoo and Johnston, 1998; Street et al., 2000; Einhorn and Lee, 2001) this delicately orchestrated process is not always successful and non-union of fractures develops in 5-20% of all patients (Einhorn, 1995; Marsh, 1998; Tzioupis and Giannoudis, 2007). Little is known about the pathogenesis of fracture non-union including the local cellular biology (Hietaniemi et al., 1998; Kloen et al., 2002; Reed et al., 2002). Fracture non-unions are generally classified into hypertrophic and atrophic non-union according to radiological criteria (Megas, 2005). Several systemic and local risk factors such as age, disease, infection and medication have been associated with the condition (Calori et al., 2007). Some cases are refractory to all existing forms of treatment, leading to numerous operative procedures, recurrent infections and treatment costs (Dahabreh et al., 2007). A range of novel biological therapies for fracture non-union have been tested clinically, including treatment with bone morphogenetic proteins (Geesink et al., 2005; Friedlaender et al., 2001; Schmidmaier et al., 2007), platelet derived growth factors (Chiang et al., 2007) and low intensity ultrasound (Khan and Laurencin, 2008). The basis of these treatments is that they are each thought to stimulate osteoblastic activity at the non-union site (Termaat et al., 2005).
A vital step in fracture healing is the recruitment of multipotent mesenchymal stromal cells (Einhorn, 1998; Oe et al., 2007) that differentiate to become chondrocytes or osteoblasts and deposit extracellular matrix (Bruder et al., 1994). There are indications however that this process is aberrant in fracture non union patients. In early studies, Hernigou and Beaujean (1997) found that bone marrow either adjacent to non-union sites of long bones or at the more distant iliac crest contains low levels of mesenchymal progenitor cells. Similarly, Seebach et al., (2007) stated that,the bone marrow of atrophic non-union patients showed a lower number of poorly proliferative fibroblast colony-forming units (CFU-F, which is previously used terminology for the mesenchymal stromal cell population) compared to multiple trauma and healthy voluntaries. Interestingly, these low levels of bone marrow derived CFU-F were also present in patients with monotrauma. In fact, Marsh et al., (2005) reported that non-union patients actually have a larger amount of multipotent stromal cells in the systemic circulation. Together these findings suggest the recruitment or redistribution of mesenchymal stromal cells from the bone marrow to the systemic pools, possibly leading to local cell engraftment, following trauma. Hofmann et al., (2008) have recently reported that osteoblastic cells can be isolated from hypertrophic non-unions but that they show reduced cell viability and capacity for mineralization. However, it is unknown whether osteoblasts precursors are present or absent at the site of human atrophic non-unions or whether their proliferation and osteoblastic activity is dysfunctional. This information is clinically relevant. It may help elucidate the biology of fracture non-union and will inform the development of novel biological therapies to substantially improve current treatment strategies.
In this study we have isolated stromal cells from tissues excised during the treatment of atrophic non-union (non-union stromal cells, NUSCs) and examined their growth and capacity to differentiate along an osteoblastic lineage in vitro. We have also assessed Dickkopf-1 (Dkk-1) secretion, which is an antagonist of the Wnt signalling pathway and a known inhibitor of fracture healing (Chen et al., 2007). This characterisation of NUSC was in comparison to stromal cells isolated from bone marrow biopsies of patients undergoinf spinal fusion operations in the treatment of back pain, who are otherwise healthy (bone marrow stromal cells, BMSCs).

Materials and Methods:
Patient demographics: Following local research committee ethical (LREC) approval and informed consent fracture non-union tissue was obtained from eight patients undergoing surgical revision of atrophic non-union (5 female, 3 male) and from iliac crest biopsies of five patients undergoing spinal fusion in the treatment of low back pain (x female, y male). The age range of non-union patients was 26 to 73 years (mean 55.6). The age range of patients undergoing spinal fusion operations was 352 to 5864 years (mean 49.452). The non-unions were longstanding (mean 3 years, range 2-5 years) and resistant to multiple previous treatments (mean 2.86, range 1-5). Three patients had tibial non-unions and five had femoral non-unions. 

Cell isolation and culture expansion.
Non-union stromal cells (NUSC):  An average 162.1 mg (range 120-250mg) of tissue was excised from the non-union site between the diaphyseal cortices below the pseudocapsule (Santavirta et al., 1992). A small sample of the harvested tissue was sent for histological analysis by the pathologists and the remainder was rinsed in sterile phosphate buffered saline (PBS; Invitrogen, Paisley, UK). Any periosteum attached to the tissue was removed and tissue embedded cells were then retrieved following enzymatic digestion with collagenase XI and centrifugation, as reported previously (Harrison et al., 2000).. The number of cells isolated by this procedure was 7.3-80 x 106 (mean 39 x 106), corresponding to a mean of 24.1 x 104 cells/ mg tissue. The cells were then plated into 250ml tissue culture flasks (BD Biosciences, Cowley, UK) in standard tissue culture medium consisting of Dulbecco’s Modified Eagle Medium/ F12 (Invitrogen) supplemented with 10% fetal bovine serum (FBS; PAA, Pasching, Austria), and antibiotics (penicillin/ streptomycin; Invitrogen). Culture flasks were incubated at 37oC in a humidified atmosphere containing 5% CO2 and any non-adherent cells were removed. The culture medium was completely changed every three to four days during cell expansion of adherent cells, until a population of stromal cells achieved ~70% confluence. The NUSC cells were initially passaged (using 0.1ml/ cm2 of 0.5g/L trypsin/ EDTA; Invitrogen) and subcultured at a seeding density of 5 x 103 cells/ cm2.
Bone marrow stromal cells (BMSC): The BMSC were isolated and cultured as previously described (Wright et al., 2008). In short, mononuclear cells isolated by density gradient centrifugation (Lymphoprep, Fresenius Kobi Norge, AS) were plated out at a seeding density of 20 x 106 per 250ml culture flask (BD Biosciences) in standard culture medium (DMEM/F12: 150% FCS, penicillin/ streptomycin). Flasks were incubated at 37oC in a humidified atmosphere containing 5% CO2. Non- adherent cells were removed after 24-72 hours and the adherent cells subsequently culture expanded until the stromal population were ~70% confluent. The BMSC were then passaged and subcultured at a density of 5 x 103 cells/ cm2 in standard culture medium, as for the NUSC. 

Growth kinetics and cell senescence: The culture doubling times (DT) of NUSC were calculated using the following equation: Doubling time = [t2 – t1]*{ln(2)/ ln [N1/ N0]} where t2 is the harvest time point, t1 is the initial time point, N1 is the cell harvest number and N0 is the initial cell number, as described previously (Wright et al., 2008). At each passage cells were trypsinised when ~70% confluent and sub-cultured into fresh culture flasks at a density of 5 x 103 cells/ cm2. Growth kinetics were investigated until cells in ceased to increase in confluence for at least 4 weeks, indicating growth arrest or cell senescence (Stenderup et al., 2003). Cell senescence was further assessed by staining for senescence associated β-galactosidase (SA- β-Gal) activity, as described by Dimri et al. (1995). For this analysis passage 2 NUSCs (n=7) and BMSCs (n=5) were cultured in 24 well plates (Starsted) and fixed in 3% formaldehyde, washed in PBS and incubated for 48 hours at 370C with 1mg/ ml X-Gal (5-bromo-4-chloro-3-indolyl β-D-galactoside, Sigma) in a buffer containing 40mM citric acid/sodium phosphate at pH 6.0 or pH 4.0, 5mM potassium ferrocyanide, 5mM potassium ferricyanide, 150mM sodium chloride and 2mM magnesium chloride. All cells stain for lysosomal β galactosidase (L-β-Gal) activity at pH 4.0, which was therefore used as a positive control, whereas staining at pH 6 is seen in senescent cells. The percentage of SA-β-Gal positive cells was determined by counting the number of positively stained cells at pH 6 in a total of 200 cells scored over five randomly selected fields of view. The presence of SA-β-Gal positive cells was also examined in non-union tissue samples using methods described by Roberts etat al., (2006). For this analysis, freshly excised tissue (n=2 non-unions: 200 mg wet weight) was incubated for 24h at 370C in SA-β-Gal staining solution at pH 4.0 or pH 6.0. After incubation the tissue was rinsed in cold PBS, snap frozen and 10µ cryosections prepared, fixed in 3% paraformaldehyde and counterstained with eosin prior to examination.

Cell differentiation status/ characterisation: 
Flow cytometry/ CD immunoprofiling: NUSC (n=4) and BMSC (n=3) were suspended in PBS  containing 2% bovine serum albumin (Sigma-Aldrich). Aliquots of cell suspensions of 2 x 105 cells were initially blocked with 10% normal human immunoglobulin (Ig) (Grifols, Cambridge, UK) then incubated at 4°C with the following fluorescently labeled mouse anti-human antibodies: CD34 and CD45 (both phycoerythrin-conjugated) and CD105 (fluorescein-conjugated) (all antibodies from Immunotools, Friesoythe, Germany). Non-specific fluorescence was determined by incubating cells with isotype-matched control antibodies (monoclonal fluorescein-conjugated IgG2a or phycoerythrin-conjugated IgG1; Immunotools). Immunoreactivity was analysed by flow cytometry using a FACScan cytofluorometer (BD Biociences, UK) and data were acquired and analysed with Cell Quest software (BD Biosciences).
Osteoblastic differentiation: NUSCs (n=7) and BMSCs (n=5) were cultured for 28 days in osteogenic conditions consisting of standard culture medium supplemented with 10nM dexamethasone (DEXex), 10mM β-glycerophosphate and 50μMg/ml ascorbic 2-phosphateacid (all from Sigma), as described by Jaiswal et al., (1997). Control cells were cultured in standard culture media alone. In both cases medium was completely replaced every 2-33-4 days. In separate experiments, BMSCs at passage 2 (n=2) were cultured in an osteogenic conditions, as outlined above, where the medium was also supplemented with recombinant human dickkopf-1 (rhDKK-1, R&D Systems, Oxon, UK) at 0, 5, 25 and 100 ng/ml. Differentiation along an osteoblastic lineage was assessed using alkaline phosphatase (ALP) activity and mineralization as differentiation markers. ALP activity was assessed by histochemical staining of cell monolayers (as described previously, Wright et al., 2008) and quantitatively by measuring the changes in optical density of p-nitrophenyl phosphate solution at 410  nm following incubation with cell monolayers using a Bio-Tek Synergy plate reader (Bio-Tek, USA). Mineralisation in monolayer cultures was quantified by elution of alizarin red staining in 1% cetylpiridinium and measured absorbance at 590 nm. For both of these quantitative analysis, ALP and mineralization was normalized for cell numbers, which were measured by propidium iodide (Sigma) incorporation at an excitation of 535 nm and emission of 617 nm. The results have been expressed as absorbance units (p-nitrophenol and alizarin red) per 105 cells.
Adipogenic differentiation: NUSCs (n=7) and BMSCs (n=5) were cultured for 28 days in adipogenic conditions consisting of standard culture medium supplemented 1μM DEXexamethasone (Sigma-Aldrich), 0.5mM 3-isobutyl-methylxanthine (Sigma-Aldrich), insulin transferin selenium (10μg/ml ITS-X 100 pre-mix) (Invitrogen), and 100μM indomethacin (Sigma-Aldrich), as described by Pittenger et al., (1999), with control cells maintained in standard culture medium alone. In both cases medium was completely replaced every 2-3 days. Differentiation along an adipogenic lineage was evaluated by cellular accumulation of neutral lipid vacuoles, histochemically stained with Oil-red O (Sigma) (Oe et al., 2007). Oil red-O accumulation was also quantified by dissolution in 100% ethanol (Sigma) and determination of optical density at 510 nm. As for osteoblast differentiation, quantitative Oil Red O accumulation was normalized for cell number (absorbance units/ 105 cells) using propidium iodide incorporation.
Chondrogenic differentiation: NUSC (n=5) and BMSC (n=2) were placed into pellet cultures in the presence of chondrogenic medium, as described by Johnstone et al., (1998). Briefly, 2 x 105 cells were centrifuged in an eppendorf tube to form a pellet which was then incubated in chondrogenic media consisting of DMEM supplemented with 100nM DEXex, 37.5μg/ ml ascorbate 2-phosphate (Sigma), insulin transferin selenium (ITS-X 100 pre-mix) (Invitrogen), 10μg/ ml ITS-X (Invitrogen), 10ng/ ml transforming growth factor-β1 (PeproTech Ltd., London, UK), 1.25μg/ml BSA (Sigma). Control pellets were cultured in standard culture medium alone. In both cases medium was completely replaced every 2-3 days. Differentiation along a chondrogenic lineage was assessed histologically by staining cryosections of cell pellets with 1% aqueous toluidine blue (Sigma).
All differentiation/ CD characterisation studies of NUSC and BMSC wereas performed on passage 2 cells.

Enzyme linked immunosorbant assay (ELISA) for human Dkk-: ELISA plates (IWAKI, Scientific Laboratory Supplies, Nottingham, UK) were incubated overnight at 4°C with monoclonal anti-human Dkk-1 antibodies (at 1.8μg/ ml PBS; MAB10962, R&D Systems), and then blocked (following washes in PBS) with 8% skimmed milk. After blocking, the plate was washed repeatedly with 0.05% Tween 20 (in 0.1M Tris HCI buffer pH 7.4). Plates were then incubated with conditioned medium from NUSC and BMSC cultures, harvested at passage 2, which had been diluted with 8% skimmed milk to fall within a linear range of standards of recombinant human Dkk-1 (0, 1, 2 and 4ng/ ml diluted in 8% milk; 1096-DK, R&D Systems). The culture conditioned medium and standard Dkk-1 solutions were incubated for 2 hours at 4°C. The plate was then washed prior to incubating for a further 1 hour at 4°C with a secondary biotinylated goat anti-human Dkk-1 antibody (250ng/ ml in PBS/BSA, BAF1096, R&D Systems), further washes, and a tertiary step of extravidin peroxidase (2μg/ml in PBS/ BSA; Sigma). Immunoreactivity was revealed using the SureBlue TMB 1 reaction (3,3’5,5’ tetramethylbenzidine; Insight, Wembley, UK), stopped after 30 minutes by the addition of 10% sulphuric acid. The optical density of each well was determined at 450nm (using 570nm as reference wavelength) on a Bio-Tek Synergy® plate reader. The Dkk-1 concentration in culture conditioned medium was calculated by linear interpolation from the standard curve and corrected for dilution. Results have been expressed as Dkk-1 levels/ per 105 cells.

Statistical analysis: The Minitab software package (version 15.0) was used for all statistical analyses. Values have been expressed as mean ± standard deviation of the mean (SD). All data were tested for normality using the Anderson-Darling test, with equal variances examined using the Bartlett’s test. For normally distributed data, statistical differences and relationships between groups were examined using the unpaired Student’s t-test or one-way ANOVA. Post hoc determinations were made using the Sstudent’sised Tukey’s test.. The Mann-Whitney U-test was used to assess differences in the proportion of cells positive for SA-β-gal, since these data were not normally distributed. Correlation between SA-β-gal positivity and culture DT was tested using Spearman’s rho, rs. For all statistical analyses, P values of <0.05 were considered significant.


ONLY UP TO HERE!
Results
These tissues showed strong variations in morphology, present in all samples. This mainly consisted of vascularised fibroblast-like cells and/or poorly cellular cartilage with occasional few bony islands on routine hematoxylin and eosin (H&E) staining. Thus, confirming a histological picture consistent with non-union (Santavirta et al., 1992; Lawton et al., 1999).
CELL MORPHOLOGY CHARACTERISTICS 
Following isolation, adherent cells showed a fibroblastic or stromal morphology. NUSCs subsequently proliferated to form several colonies. This morphology is typical of mesenchymal progenitor including BMSCs. In addition, in 6 of the 8 isolates it was notable that some adherent cells with an extensive stellate morphology were also present. Stellate cells have been reported in degenerative connective tissues; including osteoarthritic cartilage (Bush and Hall, 2003) and intervertebral disc (Hellio et al., 2001; Johnson and Roberts, 2003). These stellate cells proliferated in vitro, however with time they formed a smaller proportion of the total cells present as the stromal cells proliferated through forming a subconfluent monolayer. Enlarged cuboidal cells, with stress fibres apparent, were also a feature of many cultures in the first passage. This morphology has been associated with cell senescence (Stenderup et al., 2003; Nyunoya et al., 2006). 
  
NON-UNION STROMAL CELLS SHOW AN IMMUNOPROFILE SIMILAR TO BMSC
The cell-surface antigen profile of adherent NUSCs was analysed and compared with that of BMSCs. Both NUSCs (60–90%) and BMSCs were positive (85–99%) for the multipotent stromal cell-related marker CD105 (SH2) (Pittenger et al., 1999; Colter et al., 2001; Tuli et al., 2003) but negative for haematopoietic markers CD34 and CD 35.

NON-UNION STROMAL CELLS SHOW A MULTIPOTENT POTENTIAL IN VITRO.
After four weeks incubation under chondrogenic conditions, NUSCs and BMSCs cell pellets had a spherical appearance. Most of the pellets from the differentiation groups were >0.4 mm in diameter. Conversely, all the pellets in the control groups were <0.35 mm. The development of a cartilagenous matrix in the cell pellets was confirmed in both NUSCs and BMSCs by staining the proteoglycans with toluidine blue. NUSCs pellets showed a greater amount of staining; in contrast a smaller amount of stained cartilage matrix was evident in the control groups. There was no visible difference between BMSCs and NUSCs. The presence collagen type II in the pellets was confirmed by immunohistochemistry – still to do 
After culture in an adipogenic media differentiation was evident with the formation of phase-bright fat vacuoles. Also, neutral lipid vacuoles were visualised by staining with oil-red O showing bright red lipid droplets. The level of oil-red O positive lipid droplets normalized per 10,000 cells for NUSCs was significantly higher than under control conditions at four weeks (t=5.42, p=<0.0001). Similarly, BMSCs adipogenesis was significantly higher than control (t=9.58, p=<0.0001). However, NUSCs adipogenic differentiation was significantly lower than for BMSCs (t=7.50, p=<0.0001), indicating a lower capacity for NUSCs adipogenic differentiation. 

NON-UNION STROMAL CELLS SHOW A DECREASED OSTEOGENIC POTENTIAL IN VITRO.
NUSCs and BMSCs were cultured under conditions favourable for osteogenic differentiation as previously described (Jaiswal et al., 1997). Following two and four weeks in culture, both NUSCs and BMSCs showed an increase in ALP activity as shown on histochemical staining. In addition, it was noticed that in all samples, a very small number of cells ~1% differentiated towards an adipogenic linage evidenced as phase-bright lipid droplets as previously reported. The level of ALP activity normalised per 10,000 cells for NUSCs under osteogenic conditions was significantly higher than under control conditions increasing from two (t=3.51, p=0.001) to four weeks (t=4.68, p=<0.0001). However, incubation of NUSCs in osteogenic conditions led to only small amounts of mineralised matrix as evidenced by Alazarin Red staining. In fact, there was no significant difference in the levels of alizarin red positive mineralized matrix for NUSCs between differentiation and control groups at four weeks (t=1.23, p=0.07). On the other hand, BMSCs were able to differentiate into an osteoblastic phenotype as evidenced in significant levels of ALP formation at two (t=7.65, p=<0.0001), four weeks (t=10.47, p=<0.0001) and mineralised matrix formation in vitro at four weeks (t=4.94, p=<0.0001). Thus, NUSCs showed a lower ability for osteogenesis in vitro than BMSCs. The ALP levels in NUSCs was significantly lower than for BMSCs at both two (t=8.54, p=<0.0001) and four (t=6.39, p=<0.0001) weeks. Similarly, the ability for mineralised matrix formation was significantly lower for NUSCs than BMSCs (t=5.71, p=<0.0001).
  
NUSCs SECRETE ELEVATED DKK-1 LEVELS DURING OSTEOGENIC DIFFERENTIATION
Following two and four weeks culture in osteogenic differentiation media, both NUSCs and BMSCs showed an increase in Dkk-1 secretion in their culture media, when compared to control. The level of Dkk-1 secretion normalised per 10,000 cells for NUSCs was significantly higher in the osteogenic media than culture in control media increasing from two (t=6.97, p=<0.0001) to four weeks (t=6.61, p=<0.0001). Similarly, BMSCs showed increased Dkk-1 secretion, at both two (t=2.70, p=<0.013) and increasing to four weeks (t=4.38, p=<0.0001). As shown above these cells were able to differentiate into an osteoblastic phenotype. However, the level of Dkk-1 secretion by NUSCs was significantly higher than BMSCs at both two (t=4.46, p=<0.0001) and four (t=4.18, p=<0.0001) weeks. 

ADDITION OF rhDkk-1 INHIBITS OSTEOGENESIS IN BMSCs
Of interest, addition of rhDkk-1 at 5, 25 and 100ng/ml led to the inhibition of osteogenic differentiation in healthy BMSCs. ALP levels at two (F=6.74, p=0.001) and four (F=11.02, p=<0.0001) weeks were significantly lower than those without addition of any rhDkk-1. There was no significant difference at two and four weeks in ALP levels between the control media? and osteogenic media with addition of 5, 25, and 100 ng/ml rhDkk-1. The levels of added rhDkk-1 are similar to those found to be secreted by NUSCs during induction of osteogenic differentiation.     

NUSCs AND BMSCs SECRETE HIGH Dkk-1 LEVELS DURING ADIPOGENIC DIFFERENTIATION
NUSCs and BMSCs both showed an increase in Dkk-1 levels in their culture media. The level of Dkk-1 secretion normalised per 10,000 cells for NUSCs was significantly higher than in control media increasing at two (t=5.06, p=<0.0001) and four weeks (t=8.79, p=<0.0001). Similarly, BMSCs showed increased Dkk-1 secretion, at two (t=7.03, p=<0.0001) and four weeks (t=4.38, p=<0.0001). The level of Dkk-1 secretion by NUSCs was significantly higher than BMSCs at both two (t=2.81, p=<0.003) and four (t=3.17, p=<0.008) weeks. Nevertheless, the difference between both cell types was much smaller than that found during osteogenesis. 

NON-UNION STROMAL CELLS EXHIBIT SENESCENCE BOTH ON GROWTH KINETICS AND BIOMARKER STAINING. 
Growth kinetics showed that NUSCs reached primary confluence at mean 15.5, +/-1.4 (SD) days. Baxter et al., (2004) reported that non-senescent BMSCs reached primary confluence in 10.4, +/-1.0 days while senescent BMSCs took 19.4, +/-4.4 days to reach primary confluence. In addition, NUSCs showed prolonged DT between passage 1-2 (mean 12.5, +/-5.6 days) and passage 2-3 (mean 16.4, +/-7.6 days). However, at passage 2-3 two donor samples had already reached growth arrest. Wright et al., (2008) at our institution using same culture conditions reported that healthy BMSCs have a shorter DT at passage 1-2 than NUSCs (mean 8.2, +/-3.3 days). Positive β-Gal cells showed an intense perinuclear blue precipitate. It is known that most cells express a lysosomal β-Gal (L- β-Gal) that is optimally active at about pH 4 (Kurz et al., 2000). Indeed a large majority of both the NUSCs and BMSCs (range 84.5 – 99.5%, median 94.4%) stained equally well for non-senescent lysosomal β-Gal when assayed at pH 4. Conversely, BMSCs showed very few positive cells at pH 6 (range 0.5 – 3.33%, median 1.50%). On the other hand, NUSCs showed a significantly larger amount of positive cells (median 17.25%, range 9.7 – 33.5 %) for SA-β-Gal (p = 0.0043). At pH 6, it was shown that senescent cells stain positive (Dimri et al., 1995). There was no significant correlation when the percentage of senescent cells was plotted against the patient’s age, number of previous operative procedures or fracture age. On the other hand, the percentage positive β-Gal NUSCs showed a positive correlation with DT at passage 1-2 (Spearman rank, rs=0.833). Thus, this confirms that positive β-Gal is related to the senesence growth kinetics. Again, the presence of SA-β-Gal cells was confirmed in excised fresh tissue. There was an evident regional variation in the same tissues, with predominantly positive areas (~85% positive) and areas with few positive cells (0-15%). Thus, senescence was not secondary to the cells isolation and culture.

Discussion
Fracture non-unions are clinically challenging. In particular, atrophic non-unions have been described as the most difficult to treat; possibly due to a failure of local biology. However, little is known about the pathogenesis, in particular the cell biology. Recently, multipotent stromal cells including BMSCs have been advocated for the treatment of non-union. However, we do not know if these cells are actually present at the fracture non-union site or if they are osteogenically proficient. To this end, we evaluated the isolation and characterisation of multipotent stromal cells from long standing and refractory atrophic fracture non-unions. Thereafter, we examined if differentiation, Dkk-1 secretion and senescence are altered in these patients. 

For the first time, this study demonstrates that cells with stromal characteristics including a CD105 positive and CD34/45 negative immunoprofile are present in human atrophic non-union tissues. These cells showed potential for multilineage differentiation in vitro, including chondrogenic and adipogenic differentiation. However, more importantly the osteogenic differentiation based on ALP positive cells and mineralization was significantly lower in NUSCs. Also we report that during ostoegenic differentiation NUSCs secrete high levels of Dkk-1, a known inhibitor of Wnt signaling (  ). In addition, we found that these levels of Dkk-1 inhibit differentiation of healthy BMSCs in vitro indicating that Dkk-1 might be a major regulator of NUSCs osteogenic differentiation and fate determination. These observations are consistent with the well established role of Wnt signaling in osteogenesis (  ).  Another major finding was that NUSCs both in vitro and in freshly excised tissues show evidence of cell senescence based on morphology, growth kinetics and SA-β-Gal staining. Surprisingly, some of our results agree with studies on osteoblasts isolated from hypertrophic non-unions. Hofmann et al., 2008, reported that these osteoblasts showed poor cell proliferation and decreased osteoblastic differentiation, related to a downregulation of β-catenin/WNT based on gene-array studies. This might indicate that the two types of non-unions (atrophic and hypertrophic) are more pathogenically similar then previously thought  implying similar treatment strategies might be needed. 

In the last decade, β-catenin was found to be a key regulator of embryonic bone development (Yang, 2003) and joint formation (Guo et al., 2004). In addition, in mature animals it is an important regulator of bone mass (Little et al., 2002; Boyden et al., 2002) and fracture healing (Chen et al., 2007). β-catenin is controlled by proteins synthesized by a group of highly evolutionary-conserved wingless (Wnt) genes. Wnt ligands bind to transmembrane complexes including low-density lipoprotein receptor-related protein 5/6 (LRP5/6) and frizzled receptors. This leads to the activation of β-catenin, nuclear translocation and transcription of several genes complexes involved in cell differentiation, cell migration, cell proliferation and regeneration (Moon et al., 2002). Several regions of the Wnt pathway were shown to be essential for bone development (Holmen et al., 2004), as well as appendicular (Kim et al., 2007) and craniofacial bone repair (Leucht et al., 2008). In addition, Wnt responsive genes are upregulated during fracture healing (Hadjiargyrou et al., 2002). Wnt signalling is controlled by several regulators, including four Dkk proteins (Westendorf et al., 2004). The best characterised is Dkk-1; a soluble inhibitor of canonical Wnt signalling which binds to LRP5/6 and Kremen proteins, inducing internalisation of the Wnt receptors (Bafico et al., 2001; Mao et al., 2002). Dkk-1 has been implicated in the development of several conditions including myeloma bone disease (Tian et al., 2003; Kaiser et al., 2006), and rheumatoid arthritis (Diarra et al., 2007) through the suppression of osteoblast differentiation (Morvan et al., 2006). In this study, we have shown that Dkk-1 is secreted in high amounts during the osteogenic differentiation of NUSCs isolated from human atrophic non-unions. The latter is important since in vitro culture of healthy BMSCs with equivalent levels of rhDKK-1 similarly inhibits their osteogenic differentiation. Inhibition of osteogenic differentiation in BMSCs by rhDKK-1 was already reported by other centres (Gregory et al., 2005). As we show here NUSCs show poor osteogenic differentiation and mineralization. On the other hand, NUSCs were able to undergo good chondrogenic differentiation in vitro. However, we did not quantify the levels of differentiation or measure corresponding DKK-1 levels for the latter. These findings are consistant with previous studies showing that inhibition of β-catenin leads to arrest of osteoblastic differentiation, and a shift in multipotent stromal cells to develop a chondrogenic phenotype (Day et al., 2005). Also, we have observed that Dkk-1 secretion is high during adipogenic differentiation in both NUSCs and BMSCs. Previous reports showed that high β-catenin/Wnt levels are important to block adipogenic differentiation and alter the cell fate towards osteogenesis (De Boer et al., 2004; Li et al., 2008).  Also, Dkk-1 was shown to increase adipogenic differentiation of primary rat calvarial cells while inhibiting osteogenic differentiation (Morvan et al., 2006). Similarly, we have observed that a small number of NUSCs adopt an adipogenic morphology under osteogenic differentiation condition.  Thus, Dkk-1 in NUSCs might represent an important factor in fate determination between the osteogenic and adipogenic lineage. 

It was previously reported in mouse models that overproduction of Dkk-1 induced an inhibition of appendicular (Chen et al., 2007) and craniofacial (Leucht et al., 2008) bone repair. Thus, we hypothesise that elevated Dkk-1 secretion is an important factor in the development and maintenance of atrophic non-unions in humans. This opens opportunities for novel biological and pharmacological therapies. These include the use of Dkk-1 neutralizing antibodies (anti-Dkk-1). Their systemic administration was reported to increase bone formation in multiple myeloma (Yaccoby et al., 2007) and rheumatoid arthritis (Diarra et al., 2007) mouse models where Dkk-1 levels were elevated, similarly to non-union. Also, the use of lithium is interesting since it was reported to induce upregulation of β-catenin and activation of Wnt signalling, leading to enhancement of fracture healing in mice (Chen et al., 2007). 

Our findings on differentiation patterns were further accompanied by the presence of senescence in NUSCs. Senescence is a permanent state of non-dividing cells and entails an irreversible arrest in the transition phase G1-S of the cell cycle (Oshima and Campisi, 1991; Pang and Chen, 1994). This ensues in most somatic cells following a finite number of cell divisions (Hayflick and Morehead, 1961) and results from both telomere independent and telomere dependent factors, the latter associated with a shortening of chromosomal telomeres. Senescence is thought to be one of the mechanisms involved in ageing and in the development of certain pathological conditions including intervertebral disc prolapse (Roberts et al., 2006). We have shown that NUSCs exhibit a typical senescent morphology with a larger cuboidal size, and multiple stress fibres (Kassem et al., 1997, Gorgoulis et al., 2005, Bonab et al., 2006). Growth kinetics showed a prolongation of the doubling time when compared to BMSCs from other studies (Baxter et al., 2004; Bonab et al., 2006; Wright et al., 2008). SA-β-Gal has been readily used as a biomarker of senescence (Dimri et al., 1995). This marker is thought to be due to a replicative age-dependent increase in the cellular content of acid β-D-galactosidase, a eukaryotic hydrolase localized in the lysosome (Kurz et al., 2000). In this study we found a significantly higher number of senescent positive cells in NUSCs when compared to BMSCs. In addition, the level of SA-β-Gal positivity significantly correlated with the cell doubling times from different patients indicating that SA-β-Gal was a reliable marker of senescence in NUSCs. SA-β-Gal positive cells were further confirmed in freshly excised non-union tissue showing that the phenomenon was not related to the process of cell isolation and culture. Thus, these results indicate that senescence might be pathologically involved in atrophic fracture non-unions. However, we cannot ascertain how and why cell senescence developed. Since these patients had resistant non-union which underwent multiple procedures, senescence might be secondary to multiple population doublings in vivo by endogenous stromal cells an attempt to heal the fracture over many years. Thus, the cells would reach the “Hayflick number” and deplete their replicative potential. The role of inappropriate biomechanics in the development of fracture non-unions has been widely debated (Carter et al., 1998). It is well known that inappropriate loading can lead to stress induced premature senescence of chondrocytes (Martin et al., 2003, Martin et al., 2004) and fibroblasts (Stanley et al., 2005). Thus, this abnormal biomechanical loading might lead to the high levels of senescence we describe in non-union tissue.

The influence of senescent cells on the healing process also requires investigation. Senescence was found to be associated with alterations in cellular morphology and function. These cells are known to secrete increased amounts of matrix metalloproteinase (MMP) enzymes (West et al., 1989). This is consistent with non-union studies by Henle et al., (2005). The authors reported an altered balance of collagenolytic? enzymes in the serum of non-union patients and low level of the respective inhibitors termed, tissue inhibitors of matrix metalloproteinases. In addition, gene expression in senescent cells is characterised by a less fibrogenic and a more pronounced inflammatory phenotype (Shelton et al., 1999, Schnabl et al., 2003). In fact, senescence response substantially overlaps gene expression patterns observed in activated fibroblast during wound healing (Shelton et al., 1999). Inflammatory molecules were found to be overexpressed in senescent cells, these include chemokines MCP-1 and Gro-α, cytokines IL-15 and IL-1β, the interlukin-1 receptor homolog Toll protein (Tlr-4) and intercellular adhesion molecule-1 (ICAM-1 or CD54) (Shelton et al., 1999; Gorgoulis et al., 2005). Thus, this may mimic a propagated inflammatory response which could disrupt matrix repair and prevent the completion of normal wound healing (Shelton et al., 1999). Although, we have not studied the relationship between senescence, inflammation and Dkk-1 expression; Diarra et al., (2007) reported that Dkk-1 secretion in joint disease is modulated by inflammatory molecules including TNF and abrogated by treatment with anti-TNF. Thus, they report that inflammation is a major pathophysiological inducer of Dkk-1 expression. Even though, this relationship needs further study in the case of non-union, senescence might be an inducer of Dkk-1 secretion in NUSCs. On the other hand, in vitro studies have shown that short-term exposure of BMSCs to rhDKK-1 induced proliferation, whereas long-term exposure to high levels caused loss of viability (Gregory et al., 2003). Thus, high levels of Dkk-1, in addition to blocking osteogenesis, might be an inducer of senescence. 

In the current studies we show that BMSCs have a significantly higher proliferation, osteogenesis and mineralization ability than NUSCs. These results have further therapeutic implications, in particular for the use of cell-based tissue engineering (Bajada et al., 2008). We have previously reported that the implantation of culture expanded BMSCs led to clinical and radiological union of a long standing hypertrophic human fracture non-union (Bajada et al., 2007). Similarly, our current results show that the use of BMSCs implantation for atrophic non-unions is warranted. This could be successfully, due to the augmentation of the senescent tissue with active and osteogenically competent cells. In addition, Politou et al., 2006 reported that in multiple myeloma patients, autologous stem cell implantation led to a sustained decrease in serum Dkk-1 levels over time while bone formation increased, thus suggesting that even BMSCs implantation alone might lead to normalisation of local osteoblast function. 

Conclusion and perspective
This study, presents evidence that endogenous stromal cells from refractory and long-standing atrophic non-unions show cell senescence and decreased osteogenic potential with secretion of elevated Dkk-1 levels in vitro. We suggest that these results show new perspectives on the cell biology and open new opportunities for success in the treatment of non-union. The development of novel biological therapies based of BMSCs implantation and modulation of Dkk-1 signalling are attractive future options. 
Acknowledgments
These studies have been funded by the Institute of Orthopaedics, Oswestry, UK.

Conflict of interest




1.	Bafico A, Liu G, Yaniv A, Gazit A, Aaronson SA. (​http:​/​​/​www.ncbi.nlm.nih.gov​/​pubmed​/​11433302?ordinalpos=1&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum​) Novel mechanism of Wnt signalling inhibition mediated by Dickkopf-1 interaction with LRP6/Arrow. Nat Cell Biol. 2001 Jul;3(7):683-6.
2.	Bajada S, Harrison PE, Ashton BA, Cassar-Pullicino VN, Ashammakhi N, Richardson JB. (​http:​/​​/​www.ncbi.nlm.nih.gov​/​pubmed​/​17957083?ordinalpos=2&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum​) Successful treatment of refractory tibial nonunion using calcium sulphate and bone marrow stromal cell implantation. J Bone Joint Surg Br. 2007 Oct;89(10):1382-6.
3.	Bajada S, Mazakova I, Richardson JB, Ashammakhi N. (​http:​/​​/​www.ncbi.nlm.nih.gov​/​pubmed​/​18493906?ordinalpos=1&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum​) Updates on stem cells and their applications in regenerative medicine. J Tissue Eng Regen Med. 2008 Jun;2(4):169-83.
4.	Baxter MA, Wynn RF, Jowitt SN, Wraith JE, Fairbairn LJ, Bellantuono I. (​http:​/​​/​www.ncbi.nlm.nih.gov​/​sites​/​entrez?Db=pubmed&Cmd=ShowDetailView&TermToSearch=15342932&ordinalpos=20&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum​) Study of telomere length reveals rapid aging of human marrow stromal cells following in vitro expansion. Stem Cells. 2004;22(5):675-82. 
5.	Bonab MM, Alimoghaddam K, Talebian F, Ghaffari SH, Ghavamzadeh A, Nikbin B. (​http:​/​​/​www.ncbi.nlm.nih.gov​/​sites​/​entrez?Db=pubmed&Cmd=ShowDetailView&TermToSearch=16529651&ordinalpos=1&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum​) Aging of mesenchymal stem cell in vitro. BMC Cell Biol. 2006 Mar 10;7:14. 
6.	Boyan BD, Caplan AI, Heckman JD, Lennon DP, Ehler W, Schwartz Z. (​http:​/​​/​www.ncbi.nlm.nih.gov​/​pubmed​/​10221842?ordinalpos=17&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum​)  Osteochondral progenitor cells in acute and chronic canine nonunions. J Orthop Res. 1999 Mar;17(2):246-55.
7.	Boyden LM, Mao J, Belsky J, Mitzner L, Farhi A, Mitnick MA, Wu D, Insogna K, Lifton RP. (​http:​/​​/​www.ncbi.nlm.nih.gov​/​pubmed​/​12015390?ordinalpos=1&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum​) High bone density due to a mutation in LDL-receptor-related protein 5. N Engl J Med. 2002 May 16;346(20):1513-21. 
8.	Bruder SP, Fink DJ, Caplan AI. (​http:​/​​/​www.ncbi.nlm.nih.gov​/​pubmed​/​7876320?ordinalpos=1&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum​) Mesenchymal stem cells in bone development, bone repair, and skeletal regeneration therapy. J Cell Biochem. 1994;56(3):283-94.
9.	Bush PG, Hall AC. (​http:​/​​/​www.ncbi.nlm.nih.gov​/​sites​/​entrez?Db=pubmed&Cmd=ShowDetailView&TermToSearch=12681950&ordinalpos=8&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum​) The volume and morphology of chondrocytes within non-degenerate and degenerate human articular cartilage. Osteoarthritis Cartilage. 2003 Apr;11(4):242-51. 
10.	Calori GM, Albisetti W, Agus A, Iori S, Tagliabue L. (​http:​/​​/​www.ncbi.nlm.nih.gov​/​pubmed​/​17920412?ordinalpos=3&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum​) Risk factors contributing to fracture non-unions. Injury. 2007 May;38 Suppl 2:S11-8. 
11.	Carter DR, Beaupré GS, Giori NJ, Helms JA. (​http:​/​​/​www.ncbi.nlm.nih.gov​/​sites​/​entrez?Db=pubmed&Cmd=ShowDetailView&TermToSearch=9917625&ordinalpos=9&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum​) Mechanobiology of skeletal regeneration. Clin Orthop Relat Res. 1998 Oct;(355 Suppl):S41-55.
12.	Chen Y, Whetstone HC, Lin AC, Nadesan P, Wei Q, Poon R, Alman BA. (​http:​/​​/​www.ncbi.nlm.nih.gov​/​pubmed​/​17676991?ordinalpos=1&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum​) Beta-catenin signaling plays a disparate role in different phases of fracture repair: implications for therapy to improve bone healing. PLoS Med. 2007 Jul 31;4(7):e249.
13.	Chiang CC, Su CY, Huang CK, Chen WM, Chen TH, Tzeng YH. (​http:​/​​/​www.ncbi.nlm.nih.gov​/​pubmed​/​18073616?ordinalpos=1&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum​) Early experience and results of bone graft enriched with autologous platelet gel for recalcitrant nonunions of lower extremity. J Trauma. 2007 Sep;63(3):655-61.
14.	Colter DC, Sekiya I, Prockop DJ. (​http:​/​​/​www.ncbi.nlm.nih.gov​/​sites​/​entrez?Db=pubmed&Cmd=ShowDetailView&TermToSearch=11427725&ordinalpos=12&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum​) Identification of a subpopulation of rapidly self-renewing and multipotential adult stem cells in colonies of human marrow stromal cells. Proc Natl Acad Sci U S A. 2001 Jul 3;98(14):7841-5.
15.	Dahabreh Z, Dimitriou R, Giannoudis PV. (​http:​/​​/​www.ncbi.nlm.nih.gov​/​pubmed​/​17070526?ordinalpos=2&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum​) Health economics: a cost analysis of treatment of persistent fracture non-unions using bone morphogenetic protein-7. Injury. 2007 Mar;38(3):371-7. 
16.	Day TF, Guo X, Garrett-Beal L, Yang Y. (​http:​/​​/​www.ncbi.nlm.nih.gov​/​pubmed​/​15866164?ordinalpos=3&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum​) Wnt/beta-catenin signaling in mesenchymal progenitors controls osteoblast and chondrocyte differentiation during vertebrate skeletogenesis. Dev Cell. 2005 May;8(5):739-50.
17.	De Boer J, Wang HJ, Van Blitterswijk C. (​http:​/​​/​www.ncbi.nlm.nih.gov​/​pubmed​/​15165456?ordinalpos=1&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum​) Effects of Wnt signaling on proliferation and differentiation of human mesenchymal stem cells. Tissue Eng. 2004 Mar-Apr;10(3-4):393-401.
18.	 (​http:​/​​/​www.ncbi.nlm.nih.gov​/​pubmed​/​17237793?ordinalpos=1&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum​)Diarra D, Stolina M, Polzer K, Zwerina J, Ominsky MS, Dwyer D, Korb A, Smolen J, Hoffmann M, Scheinecker C, van der Heide D, Landewe R, Lacey D, Richards WG, Schett G. (​http:​/​​/​www.ncbi.nlm.nih.gov​/​pubmed​/​17237793?ordinalpos=1&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum​) Dickkopf-1 is a master regulator of joint remodeling. Nat Med. 2007 Feb;13(2):156-63. 
19.	Dimri GP, Lee X, Basile G, Acosta M, Scott G, Roskelley C, Medrano EE, Linskens M, Rubelj I, Pereira-Smith O, et al. (​http:​/​​/​www.ncbi.nlm.nih.gov​/​sites​/​entrez?Db=pubmed&Cmd=ShowDetailView&TermToSearch=7568133&ordinalpos=1&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum​) A biomarker that identifies senescent human cells in culture and in aging skin in vivo. Proc Natl Acad Sci U S A. 1995 Sep 26;92(20):9363-7. 
20.	Einhorn TA. (​http:​/​​/​www.ncbi.nlm.nih.gov​/​pubmed​/​7782368?ordinalpos=3&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum​) Enhancement of fracture-healing. J Bone Joint Surg Am. 1995 Jun;77(6):940-56. 
21.	Einhorn TA, Lee CA. (​http:​/​​/​www.ncbi.nlm.nih.gov​/​pubmed​/​11421573?ordinalpos=1&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum​) Bone regeneration: new findings and potential clinical applications. J Am Acad Orthop Surg. 2001 May-Jun;9(3):157-65.
22.	Friedlaender GE, Perry CR, Cole JD, Cook SD, Cierny G, Muschler GF, Zych GA, Calhoun JH, LaForte AJ, Yin S. (​http:​/​​/​www.ncbi.nlm.nih.gov​/​pubmed​/​11314793?ordinalpos=11&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum​) Osteogenic protein-1 (bone morphogenetic protein-7) in the treatment of tibial nonunions. J Bone Joint Surg Am. 2001;83-A Suppl 1(Pt 2):S151-8. 
23.	Geesink RG, Hoefnagels NH, Bulstra SK. (​http:​/​​/​www.ncbi.nlm.nih.gov​/​pubmed​/​10463751?ordinalpos=1&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum​) Osteogenic activity of OP-1 bone morphogenetic protein (BMP-7) in a human fibular defect. J Bone Joint Surg Br. 1999 Jul;81(4):710-8.
24.	Gorgoulis VG, Pratsinis H, Zacharatos P, Demoliou C, Sigala F, Asimacopoulos PJ, Papavassiliou AG, Kletsas D. (​http:​/​​/​www.ncbi.nlm.nih.gov​/​sites​/​entrez?Db=pubmed&Cmd=ShowDetailView&TermToSearch=15711569&ordinalpos=7&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum​) p53-dependent ICAM-1 overexpression in senescent human cells identified in atherosclerotic lesions. Lab Invest. 2005 Apr;85(4):502-11.
25.	Gregory CA, Singh H, Perry AS, Prockop DJ. (​http:​/​​/​www.ncbi.nlm.nih.gov​/​pubmed​/​12740383?ordinalpos=1&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum​)  The Wnt signaling inhibitor dickkopf-1 is required for reentry into the cell cycle of human adult stem cells from bone marrow. J Biol Chem. 2003 Jul 25;278(30):28067-78.
26.	Gregory CA, Perry AS, Reyes E, Conley A, Gunn WG, Prockop DJ. (​http:​/​​/​www.ncbi.nlm.nih.gov​/​pubmed​/​15504735?ordinalpos=2&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum​) Dkk-1-derived synthetic peptides and lithium chloride for the control and recovery of adult stem cells from bone marrow. J Biol Chem. 2005 Jan 21;280(3):2309-23. 
27.	Guo X, Day TF, Jiang X, Garrett-Beal L, Topol L, Yang Y. (​http:​/​​/​www.ncbi.nlm.nih.gov​/​pubmed​/​15371327?ordinalpos=2&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum​) Wnt/beta-catenin signaling is sufficient and necessary for synovial joint formation. Genes Dev. 2004 Oct 1;18(19):2404-17.
28.	Hadjiargyrou M, Lombardo F, Zhao S, Ahrens W, Joo J, Ahn H, Jurman M, White DW, Rubin CT. (​http:​/​​/​www.ncbi.nlm.nih.gov​/​pubmed​/​12055193?ordinalpos=1&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum​) Transcriptional profiling of bone regeneration. Insight into the molecular complexity of wound repair. J Biol Chem. 2002 Aug 16;277(33):30177-82. 
29.	Hayflick L, Moorhead PS. (​http:​/​​/​www.ncbi.nlm.nih.gov​/​sites​/​entrez?Db=pubmed&Cmd=ShowDetailView&TermToSearch=13905658&ordinalpos=7&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum​)  The serial cultivation of human diploid cell strains. Exp Cell Res. 1961 Dec;25:585-621
30.	Hellio Le Graverand MP, Sciore P, Eggerer J, Rattner JP, Vignon E, Barclay L, Hart DA, Rattner JB. (​http:​/​​/​www.ncbi.nlm.nih.gov​/​sites​/​entrez?Db=pubmed&Cmd=ShowDetailView&TermToSearch=11508433&ordinalpos=5&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum​) Formation and phenotype of cell clusters in osteoarthritic meniscus. Arthritis Rheum. 2001 Aug;44(8):1808-18. 
31.	Henle P, Zimmermann G, Weiss S. (​http:​/​​/​www.ncbi.nlm.nih.gov​/​sites​/​entrez?Db=pubmed&Cmd=ShowDetailView&TermToSearch=16199217&ordinalpos=2&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum​) Matrix metalloproteinases and failed fracture healing. Bone. 2005 Dec;37(6):791-8.
32.	Hernigou P, Beaujean F. (​http:​/​​/​www.ncbi.nlm.nih.gov​/​pubmed​/​9161546?ordinalpos=7&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum​)  [Bone marrow in patients with pseudarthrosis. A study of progenitor cells by in vitro cloning] Rev Chir Orthop Reparatrice Appar Mot. 1997;83(1):33-40. 
33.	Hietaniemi K, Lehto MU, Paavolainen P. (​http:​/​​/​www.ncbi.nlm.nih.gov​/​pubmed​/​9855241?ordinalpos=2&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum​) Major fibrillar collagens and fibronectin in an experimental nonunion: an immunohistochemical study. Acta Orthop Scand. 1998 Oct;69(5):545-9.
34.	Hofmann A, Ritz U, Hessmann MH, Schmid C, Tresch A, Rompe JD, Meurer A, Rommens PM. (​http:​/​​/​www.ncbi.nlm.nih.gov​/​pubmed​/​18314404?ordinalpos=4&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum​)  Cell viability, osteoblast differentiation, and gene expression are altered in human osteoblasts from hypertrophic fracture non-unions. Bone. 2008 May;42(5):894-906.
35.	Holmen SL, Giambernardi TA, Zylstra CR, Buckner-Berghuis BD, Resau JH, Hess JF, Glatt V, Bouxsein ML, Ai M, Warman ML, Williams BO. (​http:​/​​/​www.ncbi.nlm.nih.gov​/​pubmed​/​15537447?ordinalpos=1&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum​) Decreased BMD and limb deformities in mice carrying mutations in both Lrp5 and Lrp6. J Bone Miner Res. 2004 Dec;19(12):2033-40. 
36.	Jaiswal N, Haynesworth SE, Caplan AI, Bruder SP. (​http:​/​​/​www.ncbi.nlm.nih.gov​/​pubmed​/​9027589?ordinalpos=15&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum​) Osteogenic differentiation of purified, culture-expanded human mesenchymal stem cells in vitro. J Cell Biochem. 1997 Feb;64(2):295-312.
37.	Johnson WE, Roberts S. (​http:​/​​/​www.ncbi.nlm.nih.gov​/​sites​/​entrez?Db=pubmed&Cmd=ShowDetailView&TermToSearch=14686696&ordinalpos=1&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum​) Human intervertebral disc cell morphology and cytoskeletal composition: a preliminary study of regional variations in health and disease. J Anat. 2003 Dec;203(6):605-12. 
38.	Johnstone B, Hering TM, Caplan AI, Goldberg VM, Yoo JU. (​http:​/​​/​www.ncbi.nlm.nih.gov​/​pubmed​/​9457080?ordinalpos=15&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum​) In vitro chondrogenesis of bone marrow-derived mesenchymal progenitor cells. Exp Cell Res. 1998 Jan 10;238(1):265-72.
39.	Kaiser M, Mieth M, Liebisch P, Oberländer R, Rademacher J, Jakob C, Kleeberg L, Fleissner C, Braendle E, Peters M, Stover D, Sezer O, Heider U. (​http:​/​​/​www.ncbi.nlm.nih.gov​/​pubmed​/​18331598?ordinalpos=3&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum​) Serum concentrations of DKK-1 correlate with the extent of bone disease in patients with multiple myeloma. Eur J Haematol. 2008 Jun;80(6):490-4.
40.	Kassem M, Ankersen L, Eriksen EF, Clark BF, Rattan SI. (​http:​/​​/​www.ncbi.nlm.nih.gov​/​sites​/​entrez?Db=pubmed&Cmd=ShowDetailView&TermToSearch=9604046&ordinalpos=1&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum​) Demonstration of cellular aging and senescence in serially passaged long-term cultures of human trabecular osteoblasts. Osteoporos Int. 1997;7(6):514-24. 
41.	Khan Y, Laurencin CT. (​http:​/​​/​www.ncbi.nlm.nih.gov​/​pubmed​/​18292369?ordinalpos=1&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum​) Fracture repair with ultrasound: clinical and cell-based evaluation. J Bone Joint Surg Am. 2008 Feb;90 Suppl 1:138-44. 
42.	Kim JB, Leucht P, Lam K, Luppen C, Ten Berge D, Nusse R, Helms JA. (​http:​/​​/​www.ncbi.nlm.nih.gov​/​pubmed​/​17696762?ordinalpos=2&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum​) Bone regeneration is regulated by wnt signaling. J Bone Miner Res. 2007 Dec;22(12):1913-23.
43.	Kloen P, Doty SB, Gordon E, Rubel IF, Goumans MJ, Helfet DL. (​http:​/​​/​www.ncbi.nlm.nih.gov​/​pubmed​/​12429748?ordinalpos=1&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum​) Expression and activation of the BMP-signaling components in human fracture nonunions. J Bone Joint Surg Am. 2002 Nov;84-A(11):1909-18.
44.	Kurz DJ, Decary S, Hong Y, Erusalimsky JD. (​http:​/​​/​www.ncbi.nlm.nih.gov​/​sites​/​entrez?Db=pubmed&Cmd=ShowDetailView&TermToSearch=11017877&ordinalpos=5&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum​) Senescence-associated (beta)-galactosidase reflects an increase in lysosomal mass during replicative ageing of human endothelial cells. J Cell Sci. 2000 Oct;113 ( Pt 20):3613-22. 
45.	Lawton DM, Andrew JG, Marsh DR, Hoyland JA, Freemont AJ. (​http:​/​​/​www.ncbi.nlm.nih.gov​/​pubmed​/​9350302?ordinalpos=6&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum​) Mature osteoblasts in human non-union fractures express collagen type III. Mol Pathol. 1997 Aug;50(4):194-7.
46.	Lawton DM, Andrew JG, Marsh DR, Hoyland JA, Freemont AJ. (​http:​/​​/​www.ncbi.nlm.nih.gov​/​pubmed​/​10474688?ordinalpos=5&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum​) Expression of the gene encoding the matrix gla protein by mature osteoblasts in human fracture non-unions. Mol Pathol. 1999 Apr;52(2):92-6.
47.	Leucht P, Kim JB, Helms JA. (​http:​/​​/​www.ncbi.nlm.nih.gov​/​pubmed​/​18292349?ordinalpos=1&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum​) Beta-catenin-dependent Wnt signaling in mandibular bone regeneration. J Bone Joint Surg Am. 2008 Feb;90 Suppl 1:3-8.
48.	Li HX, Luo X, Liu RX, Yang YJ, Yang GS. (​http:​/​​/​www.ncbi.nlm.nih.gov​/​pubmed​/​18584948?ordinalpos=1&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum​) Roles of Wnt/beta-catenin signaling in adipogenic differentiation potential of adipose-derived mesenchymal stem cells. Mol Cell Endocrinol. 2008 May 17. 
49.	Little RD, Carulli JP, Del Mastro RG, Dupuis J, Osborne M, Folz C, Manning SP, Swain PM, Zhao SC, Eustace B, Lappe MM, Spitzer L, Zweier S, Braunschweiger K, Benchekroun Y, Hu X, Adair R, Chee L, FitzGerald MG, Tulig C, Caruso A, Tzellas N, Bawa A, Franklin B, McGuire S, Nogues X, Gong G, Allen KM, Anisowicz A, Morales AJ, Lomedico PT, Recker SM, Van Eerdewegh P, Recker RR, Johnson ML. (​http:​/​​/​www.ncbi.nlm.nih.gov​/​pubmed​/​11741193?ordinalpos=1&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum​) A mutation in the LDL receptor-related protein 5 gene results in the autosomal dominant high-bone-mass trait. Am J Hum Genet. 2002 Jan;70(1):11-9.
50.	 Mao B, Wu W, Davidson G, Marhold J, Li M, Mechler BM, Delius H, Hoppe D, Stannek P, Walter C, Glinka A, Niehrs C. (​http:​/​​/​www.ncbi.nlm.nih.gov​/​pubmed​/​12050670?ordinalpos=2&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum​) Kremen proteins are Dickkopf receptors that regulate Wnt/beta-catenin signalling. Nature. 2002 Jun 6;417(6889):664-7.
51.	Marsh D. (​http:​/​​/​www.ncbi.nlm.nih.gov​/​pubmed​/​9917623?ordinalpos=1&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum​) Concepts of fracture union, delayed union, and nonunion. Clin Orthop Relat Res. 1998 Oct;(355 Suppl):S22-30.
52.	Martin JA, Buckwalter JA. (​http:​/​​/​www.ncbi.nlm.nih.gov​/​sites​/​entrez?Db=pubmed&Cmd=ShowDetailView&TermToSearch=12721352&ordinalpos=18&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum​) The role of chondrocyte senescence in the pathogenesis of osteoarthritis and in limiting cartilage repair. J Bone Joint Surg Am. 2003;85-A Suppl 2:106-10. 
53.	Martin JA, Brown TD, Heiner AD, Buckwalter JA. (​http:​/​​/​www.ncbi.nlm.nih.gov​/​sites​/​entrez?Db=pubmed&Cmd=ShowDetailView&TermToSearch=15480082&ordinalpos=10&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum​) Chondrocyte senescence, joint loading and osteoarthritis. Clin Orthop Relat Res. 2004 Oct;(427 Suppl):S96-103. 
54.	Megas P. (​http:​/​​/​www.ncbi.nlm.nih.gov​/​pubmed​/​16291321?ordinalpos=1&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum​) Classification of non-union. Injury. 2005 Nov;36 Suppl 4:S30-7. 
55.	Moon RT, Bowerman B, Boutros M, Perrimon N. (​http:​/​​/​www.ncbi.nlm.nih.gov​/​pubmed​/​12040179?ordinalpos=4&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum​) The promise and perils of Wnt signaling through beta-catenin. Science. 2002 May 31;296(5573):1644-6. 
56.	Morvan F, Boulukos K, Clément-Lacroix P, Roman Roman S, Suc-Royer I, Vayssière B, Ammann P, Martin P, Pinho S, Pognonec P, Mollat P, Niehrs C, Baron R, Rawadi G. (​http:​/​​/​www.ncbi.nlm.nih.gov​/​pubmed​/​16753024?ordinalpos=1&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum​) Deletion of a single allele of the Dkk1 gene leads to an increase in bone formation and bone mass. J Bone Miner Res. 2006 Jun;21(6):934-45.
57.	Murshed M, Schinke T, McKee MD, Karsenty G. (​http:​/​​/​www.ncbi.nlm.nih.gov​/​pubmed​/​15184399?ordinalpos=3&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum​)  Extracellular matrix mineralization is regulated locally; different roles of two gla-containing proteins. J Cell Biol. 2004 Jun 7;165(5):625-30.
58.	Nyunoya T, Monick MM, Klingelhutz A, Yarovinsky TO, Cagley JR, Hunninghake GW. (​http:​/​​/​www.ncbi.nlm.nih.gov​/​pubmed​/​16840774?ordinalpos=2&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum​) Cigarette smoke induces cellular senescence. Am J Respir Cell Mol Biol. 2006 Dec;35(6):681-8. 
59.	Oe K, Miwa M, Sakai Y, Lee SY, Kuroda R, Kurosaka M. (​http:​/​​/​www.ncbi.nlm.nih.gov​/​pubmed​/​17259432?ordinalpos=2&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum​)  An in vitro study demonstrating that haematomas found at the site of human fractures contain progenitor cells with multilineage capacity. J Bone Joint Surg Br. 2007 Jan;89(1):133-8.
60.	Oshima J, Campisi J. (​http:​/​​/​www.ncbi.nlm.nih.gov​/​sites​/​entrez?Db=pubmed&Cmd=ShowDetailView&TermToSearch=1918549&ordinalpos=1&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum​) Fundamentals of cell proliferation: control of the cell cycle. J Dairy Sci. 1991 Aug;74(8):2778-87. 
61.	Pang JH, Chen KY. (​http:​/​​/​www.ncbi.nlm.nih.gov​/​sites​/​entrez?Db=pubmed&Cmd=ShowDetailView&TermToSearch=8077291&ordinalpos=2&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum​) Global change of gene expression at late G1/S boundary may occur in human IMR-90 diploid fibroblasts during senescence. J Cell Physiol. 1994 Sep;160(3):531-8.
62.	Pittenger MF, Mackay AM, Beck SC, Jaiswal RK, Douglas R, Mosca JD, Moorman MA, Simonetti DW, Craig S, Marshak DR. (​http:​/​​/​www.ncbi.nlm.nih.gov​/​pubmed​/​10102814?ordinalpos=1&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum​) Multilineage potential of adult human mesenchymal stem cells. Science. 1999 Apr 2;284(5411):143-7.
63.	Politou MC, Heath DJ, Rahemtulla A, Szydlo R, Anagnostopoulos A, Dimopoulos MA, Croucher PI, Terpos E. (​http:​/​​/​www.ncbi.nlm.nih.gov​/​pubmed​/​16646053?ordinalpos=2&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum​) Serum concentrations of Dickkopf-1 protein are increased in patients with multiple myeloma and reduced after autologous stem cell transplantation. Int J Cancer. 2006 Oct 1;119(7):1728-31.
64.	Reed AA, Joyner CJ, Brownlow HC, Simpson AH. (​http:​/​​/​www.ncbi.nlm.nih.gov​/​pubmed​/​12038636?ordinalpos=1&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum​) Human atrophic fracture non-unions are not avascular. J Orthop Res. 2002 May;20(3):593-9.
65.	Roberts S, Evans EH, Kletsas D, Jaffray DC, Eisenstein SM. (​http:​/​​/​www.ncbi.nlm.nih.gov​/​sites​/​entrez?Db=pubmed&Cmd=ShowDetailView&TermToSearch=16773379&ordinalpos=1&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum​)  Senescence in human intervertebral discs. Eur Spine J. 2006 Aug;15 Suppl 3:S312-6.
66.	Santavirta S, Konttinen YT, Nordström D, Mäkelä A, Sorsa T, Hukkanen M, Rokkanen P. (​http:​/​​/​www.ncbi.nlm.nih.gov​/​pubmed​/​1471500?ordinalpos=1&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum​) Immunologic studies of nonunited fractures. Acta Orthop Scand. 1992 Dec;63(6):579-86.
67.	Schnabl B, Purbeck CA, Choi YH, Hagedorn CH, Brenner D. (​http:​/​​/​www.ncbi.nlm.nih.gov​/​sites​/​entrez?Db=pubmed&Cmd=ShowDetailView&TermToSearch=12601363&ordinalpos=1&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum​) Replicative senescence of activated human hepatic stellate cells is accompanied by a pronounced inflammatory but less fibrogenic phenotype. Hepatology. 2003 Mar;37(3):653-64. 
68.	Schmidmaier G, Schwabe P, Wildemann B, Haas NP. (​http:​/​​/​www.ncbi.nlm.nih.gov​/​pubmed​/​18224735?ordinalpos=1&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum​) Use of bone morphogenetic proteins for treatment of non-unions and future perspectives. Injury. 2007 Sep;38 Suppl 4:S35-41.
69.	Seebach C, Henrich D, Tewksbury R, Wilhelm K, Marzi I. (​http:​/​​/​www.ncbi.nlm.nih.gov​/​pubmed​/​17431529?ordinalpos=10&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum​)  Number and proliferative capacity of human mesenchymal stem cells are modulated positively in multiple trauma patients and negatively in atrophic nonunions. Calcif Tissue Int. 2007 Apr;80(4):294-300. 
70.	Shelton DN, Chang E, Whittier PS, Choi D, Funk WD. (​http:​/​​/​www.ncbi.nlm.nih.gov​/​sites​/​entrez?Db=pubmed&Cmd=ShowDetailView&TermToSearch=10508581&ordinalpos=5&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum​) Microarray analysis of replicative senescence. Curr Biol. 1999 Sep 9;9(17):939-45.
71.	Stenderup K, Justesen J, Clausen C, Kassem M. (​http:​/​​/​www.ncbi.nlm.nih.gov​/​sites​/​entrez?Db=pubmed&Cmd=ShowDetailView&TermToSearch=14678851&ordinalpos=1&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum​) Aging is associated with decreased maximal life span and accelerated senescence of bone marrow stromal cells. Bone. 2003 Dec;33(6):919-26. 
72.	Stanley AC, Fernandez NN, Lounsbury KM, Corrow K, Osler T, Healey C, Forgione P, Shackford SR, Ricci MA. (​http:​/​​/​www.ncbi.nlm.nih.gov​/​sites​/​entrez?Db=pubmed&Cmd=ShowDetailView&TermToSearch=15734488&ordinalpos=1&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum​) Pressure-induced cellular senescence: a mechanism linking venous hypertension to venous ulcers. J Surg Res. 2005 Mar;124(1):112-7. 
73.	Street J, Winter D, Wang JH, Wakai A, McGuinness A, Redmond HP. (​http:​/​​/​www.ncbi.nlm.nih.gov​/​pubmed​/​10986998?ordinalpos=4&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum​) Is human fracture  hematoma inherently angiogenic? Clin Orthop Relat Res. 2000 Sep;(378):224-37.
74.	Termaat MF, Den Boer FC, Bakker FC, Patka P, Haarman HJ. (​http:​/​​/​www.ncbi.nlm.nih.gov​/​pubmed​/​15930551?ordinalpos=3&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum​) Bone morphogenetic proteins. Development and clinical efficacy in the treatment of fractures and bone defects. J Bone Joint Surg Am. 2005 Jun;87(6):1367-78. 
75.	Tian E, Zhan F, Walker R, Rasmussen E, Ma Y, Barlogie B, Shaughnessy JD Jr. (​http:​/​​/​www.ncbi.nlm.nih.gov​/​pubmed​/​14695408?ordinalpos=2&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum​) The role of the Wnt-signaling antagonist DKK1 in the development of osteolytic lesions in multiple myeloma. N Engl J Med. 2003 Dec 25;349(26):2483-94. 
76.	Tuli R, Seghatoleslami MR, Tuli S, Wang ML, Hozack WJ, Manner PA, Danielson KG, Tuan RS. (​http:​/​​/​www.ncbi.nlm.nih.gov​/​pubmed​/​12611268?ordinalpos=1&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum​) A simple, high-yield method for obtaining multipotential mesenchymal progenitor cells from trabecular bone. Mol Biotechnol. 2003 Jan;23(1):37-49.
77.	Tzioupis C, Giannoudis PV. (​http:​/​​/​www.ncbi.nlm.nih.gov​/​pubmed​/​17920415?ordinalpos=2&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum​) Prevalence of long-bone non-unions. Injury. 2007 May;38 Suppl 2:S3-9.
78.	Westendorf JJ, Kahler RA, Schroeder TM. (​http:​/​​/​www.ncbi.nlm.nih.gov​/​pubmed​/​15474285?ordinalpos=1&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum​) Wnt signaling in osteoblasts and bone diseases. Gene. 2004 Oct 27;341:19-39.
79.	Wright KT, Masri WE, Osman A, Roberts S, Trivedi J, Ashton BA, Johnson WE. (​http:​/​​/​www.ncbi.nlm.nih.gov​/​pubmed​/​18560372?ordinalpos=1&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum​) The cell culture expansion of bone marrow stromal cells from humans with spinal cord injury: implications for future cell transplantation therapy. Spinal Cord. 2008 Jun 17. 
80.	Yang Y. (​http:​/​​/​www.ncbi.nlm.nih.gov​/​pubmed​/​14745971?ordinalpos=2&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum​) Wnts and wing: Wnt signaling in vertebrate limb development and musculoskeletal morphogenesis. Birth Defects Res C Embryo Today. 2003 Nov;69(4):305-17. 
81.	Yaccoby S, Ling W, Zhan F, Walker R, Barlogie B, Shaughnessy JD Jr. (​http:​/​​/​www.ncbi.nlm.nih.gov​/​pubmed​/​17068150?ordinalpos=7&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum​) Antibody-based inhibition of DKK1 suppresses tumor-induced bone resorption and multiple myeloma growth in vivo. Blood. 2007 Mar 1;109(5):2106-11. 
82.	West MD, Pereira-Smith OM, Smith JR. (​http:​/​​/​www.ncbi.nlm.nih.gov​/​sites​/​entrez?Db=pubmed&Cmd=ShowDetailView&TermToSearch=2551704&ordinalpos=17&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum​)  Replicative senescence of human skin fibroblasts correlates with a loss of regulation and overexpression of collagenase activity. Exp Cell Res. 1989 Sep;184(1):138-47. 
83.	Yoo JU, Johnstone B. (​http:​/​​/​www.ncbi.nlm.nih.gov​/​pubmed​/​9917628?ordinalpos=2&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum​) The role of osteochondral progenitor cells in fracture repair. Clin Orthop Relat Res. 1998 Oct;(355 Suppl):S73-81. 

84.	

PAGE  



1



